Sunnybrook Health Science Centre

Running trials

• Recruiting

  Eary Infusion of Eptinezumab for TreatmEnt of ACute Post-Traumatic Headaches (ELITE-ACT)

  NCT07191145· Phase 3· Source

• Recruiting

  Testing a New Treatment Strategy to Improve Secondary Stroke Prevention for Older Adults: The STROKE75+ Trial

  NCT07454707· Phase 3· Source

• Not yet recruiting

  A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity

  NCT07861100· Phase 3· Source

• Recruiting

  Ketogenic Diet and Neuromodulation in Treatment Resistant Depression

  NCT07376018· Source

• Not yet recruiting

  CEST for Prostate Biopsy

  NCT07785024· Source

• Not yet recruiting

  Feasibility Evaluation of WEAR-IT for Hand Therapy After Stroke

  NCT07698067· Source

• Recruiting

  Goal-Directed Therapy to Reduce Kidney and Cardiovascular Risk in Diabetic Kidney Disease (GOLD-STANDARD)

  NCT07434791· Source

• Recruiting

  Optimized Recruitment to Drive Equitable Research in Stroke, Empowering Decision-making (ORDERed)

  NCT07576647· Source

• Recruiting

  ACT-GLOBAL IA Thrombolysis(ACT-REACT-004)Domain Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632

  NCT07687056· Phase 3· Source

• Recruiting

  DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

  NCT07544654· Phase 3· Source

• Recruiting

  Ted Rogers Understanding of Exacerbations in Heart Failure 2: Monitor

  NCT07447908· Source

• Recruiting

  A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer

  NCT07644559· Phase 2· Source

• Not yet recruiting

  Volunteer Facilitated Discharge Assistance and Supports at Home (DASH) for People With Stroke

  NCT07590076· Source

• Recruiting

  InTRavenous kEtAmine and immerSive virtUal Reality to Treat dEpression

  NCT06781697· Phase 3· Source

• Recruiting

  A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer

  NCT07405801· Phase 2· Source

• Not yet recruiting

  A Dose Optimization Study of Enzalutamide in Elderly Patients With Advanced Prostate Cancer

  NCT07512076· Phase 2· Source

• Recruiting

  Oral Versus Intramuscular Steroid Use to Control Rheumatoid Arthritis Flares

  NCT07245732· Phase 4· Source

• Active, not recruiting

  Dose-dEscalated MR-Guided Radiotherapy for Localized Prostate Cancer

  NCT07674225· Source

• Recruiting

  A Clinical Trial to Evaluate NB-4746 in Participants With Amyotrophic Lateral Sclerosis.

  NCT07369076· Phase 1/2· Source

• Not yet recruiting

  Sustained Mood Improvement With Laughing Gas Exposure

  NCT07262008· Phase 3· Source

• Recruiting

  A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection

  NCT07128199· Phase 3· Source

• Active, not recruiting

  A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

  NCT07170150· Phase 3· Source

• Recruiting

  Daily Temozolomide for Elderly Patients With Unmethylated MGMT- Promoter Newly Diagnosed GliOblatoma

  NCT07476794· Phase 2· Source

• Recruiting

  Levetiracetam for Persons at Risk for Alzheimer's Disease

  NCT07477431· Phase 2· Source

• Recruiting

  The Multicentre Selective Lymphadenectomy Trial - 3

  NCT07049276· Source

• Active, not recruiting

  Study of COYA 302 for the Treatment of ALS

  NCT07161999· Phase 2/3· Source

• Recruiting

  A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

  NCT07164443· Phase 3· Source

• Recruiting

  A Study of LY4257496 in Participants With Cancer (OMNIRAY)

  NCT07114601· Phase 1· Source

• Recruiting

  rTMS for Youth Inpatients With Depression

  NCT07140575· Source

• Recruiting

  Magnetic Resonance-Guided Focused Ultrasound Bilateral Capsulotomy for Refractory Anorexia Nervosa With Comorbid Obsessive Compulsive Disorder or Major Depressive Disorder

  NCT07113665· Phase 1· Source

• Recruiting

  Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

  NCT06943755· Phase 2/3· Source

• Recruiting

  A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy

  NCT06963827· Phase 3· Source

• Recruiting

  Focused Ultrasound Neuromodulation in Patients With Treatment-Resistant Depression

  NCT07094789· Source

• Recruiting

  Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies

  NCT07177352· Phase 3· Source

• Recruiting

  Magnetic Resonance-Guided Focused Ultrasound Bilateral Capsulotomy for the Treatment of Refractory Bipolar Depression

  NCT07108257· Source

• Recruiting

  Left Atrial Imaging Prior to Cardioversion: Leveraging Computed Tomography to Rule Out Thrombus in The Emergency Department (LA CLOTTED)

  NCT07002450· Source

• Recruiting

  Focused Ultrasound Blood-Brain Barrier Disruption for the Treatment of High-Grade Glioma in Patients Undergoing Standard Chemotherapy

  NCT07179328· Phase 1· Source

• Recruiting

  A Randomized Neuroimaging Trial of Psilocybin in Depression

  NCT06072898· Phase 2· Source

• Recruiting

  Screening for Prostate Cancer Using High Resolution Micro-ultrasound Versus Multiparametric Magnetic Resonance Imaging.

  NCT06626022· Phase 3· Source

• Recruiting

  Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial - Part 2

  NCT07227246· Phase 3· Source

• Recruiting

  Life Following Excision of Neuroendocrine Tumors

  NCT06981455· Source

• Recruiting

  A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

  NCT06827236· Phase 1/2· Source

• Active, not recruiting

  Intravenous Immunoglobulin (IVIG) and Blood-Brain Barrier Disruption in Amyotrophic Lateral Sclerosis (ALS)

  NCT07193953· Phase 1· Source

• Recruiting

  A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

  NCT06790693· Phase 3· Source

• Recruiting

  The HEROES Trial: Hyperbaric Oxygen Therapy for Endometriosis-Related Pain

  NCT06579040· Source

• Recruiting

  Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer

  NCT06801834· Phase 3· Source

• Recruiting

  Accelerated vs. Conventional Theta Burst Stimulation for Late-life Depression

  NCT06854367· Source

• Enrolling by invitation

  Assessment of Worldwide Acute Kidney Injury Epidemiology in Neonates 2.0

  NCT06823115· Source

• Recruiting

  Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

  NCT06731478· Phase 3· Source

• Active, not recruiting

  Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer

  NCT06619236· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Prostate cancer13 recruiting
• Depression12 recruiting
• Metastatic breast cancer12 recruiting
• Alzheimer disease11 recruiting
• Childhood cancers10 recruiting
• Stroke9 recruiting
• Head and neck cancer6 recruiting
• Atrial fibrillation5 recruiting
• Coronary artery disease4 recruiting
• Heart failure4 recruiting
• Lung cancer4 recruiting
• Melanoma4 recruiting
• ALS (motor neurone disease)3 recruiting
• Colorectal cancer3 recruiting
• Frontotemporal dementia3 recruiting
• Glioblastoma3 recruiting
• Neuroendocrine tumours3 recruiting
• Pancreatic cancer3 recruiting
• Bipolar disorder2 recruiting
• Chronic kidney disease2 recruiting
• Gastric and esophageal cancer2 recruiting
• High blood pressure2 recruiting
• Lewy body dementia2 recruiting
• Acute myeloid leukemia1 recruiting
• Asthma1 recruiting
• Cervical cancer1 recruiting
• Chronic myeloid leukaemia1 recruiting
• Endometrial cancer1 recruiting
• Endometriosis1 recruiting
• IgA nephropathy1 recruiting
• Migraine1 recruiting
• Myelodysplastic syndromes1 recruiting
• Obesity1 recruiting
• Ovarian cancer1 recruiting
• Parkinson disease1 recruiting
• Rheumatoid arthritis1 recruiting
• Type 1 diabetes1 recruiting
• Type 2 diabetes1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease

  NCT06926660· Phase 2· Source

• Completed

  Study to Assess Function and Satisfaction of Oral Ubrogepant in Adult Participants After Multiple Migraine Attacks In Canada

  NCT06692881· Source

• Completed

  FET-PET/MRI Based Treatment Planning for Glioblastoma Multiforme in Post-Surgical Patients (FET-TREAT)

  NCT06451042· Source

• Terminated

  Continuation Study for Latozinemab

  NCT06111014· Phase 3· Source

• Recruiting

  Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement

  NCT05727176· Phase 2· Source

• Terminated

  Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers

  NCT05860296· Phase 1/2· Source

• Terminated

  Nabilone for Agitation in Frontotemporal Dementia

  NCT05742698· Phase 2· Source

• Completed

  A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  NCT05686070· Phase 3· Source

• Completed

  TESTING -ON Post-Trial ObservatioNal Cohort Study

  NCT05434325· Source

• Terminated

  Anticoagulation Therapy Timing in Atrial Fibrillation After Acute and Chronic Subdural Hematoma

  NCT05472766· Source

• Terminated

  A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Canada

  NCT05424562· Source

• Completed

  Optina Diagnostics' Cerebral ß-Amyloid Status (CAS) Test

  NCT05107882· Source

• Terminated

  A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

  NCT05310071· Phase 3· Source

• Completed

  Optimization of Prostate Biopsy - Micro-Ultrasound Versus MRI

  NCT05220501· Source

• Completed

  Does Eliminating Coffee Avoid Fibrillation?

  NCT05121519· Source

• Completed

  Closed-loop Insulin Delivery In Type 1 Diabetes Pregnancies (CIRCUIT)

  NCT04902378· Source

• Completed

  A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)

  NCT04777396· Phase 3· Source

• Completed

  A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)

  NCT04777409· Phase 3· Source

• Completed

  UNIty-Based MR-Linac Guided AdapTive RadiothErapy for High GraDe Glioma: a Phase 2 Trial

  NCT04726397· Source

• Completed

  Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61)

  NCT04704219· Phase 2· Source

• Completed

  Exablate Blood-Brain Barrier Disruption With Carboplatin for the Treatment of rGBM

  NCT04440358· Phase 1/2· Source

• Completed

  A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression

  NCT04209855· Phase 3· Source

• Completed

  A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2)

  NCT03987295· Phase 2· Source

• Completed

  EdoxabaN foR IntraCranial Hemorrhage Survivors With Atrial Fibrillation (ENRICH-AF)

  NCT03950076· Phase 4· Source

• Completed

  Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

  NCT03781063· Phase 2· Source

• Completed

  Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced, Unresectable Pancreatic Cancer

  NCT03941093· Phase 3· Source

• Completed

  ExAblate Blood-Brain Barrier Opening for Treatment of Alzheimer's Disease

  NCT03739905· Source

• Completed

  Using Exercise and Electrical Brain Stimulation to Improve Memory in Dementia

  NCT03670615· Source

• Completed

  Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption for Treatment of Glioma

  NCT03616860· Source

• Completed

  A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)

  NCT03516981· Phase 2· Source

• Completed

  This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS)

  NCT03599245· Phase 3· Source

• Completed

  Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])

  NCT03517449· Phase 3· Source

• Completed

  A Study of INCB050465 in Relapsed or Refractory Follicular Lymphoma

  NCT03126019· Phase 2· Source

• Completed

  Colchicine and Spironolactone in Patients with MI / SYNERGY Stent Registry

  NCT03048825· Phase 3· Source

• Completed

  Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)

  NCT03268954· Phase 3· Source

• Completed

  Does Cefoxitin or Piperacillin-Tazobactam Prevent Postoperative Surgical Site Infections After Pancreatoduodenectomy?

  NCT03269994· Phase 3· Source

• Completed

  A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma

  NCT03274492· Phase 3· Source

• Completed

  Novel Echocardiographic Methods for Early Identification of Neonates at Risk for Chronic Pulmonary Hypertension

  NCT04402645· Source

• Completed

  Alzheimer's Disease Neuroimaging Initiative 3

  NCT02854033· Source

• Completed

  Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver

  NCT02724540· Phase 2· Source

• Completed

  Optimal Anticoagulation for Higher Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial

  NCT02168829· Phase 4· Source

• Recruiting

  JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer

  NCT02468024· Phase 3· Source

• Completed

  A Randomized Controlled Trial of TNK-tPA Versus Standard of Care for Minor Ischemic Stroke With Proven Occlusion

  NCT02398656· Phase 3· Source

• Withdrawn

  Improving Outcomes After Time Sensitive Prehospital Interventions: Rescu Epistry

  NCT04110912· Source

• Completed

  Amyloid and Glucose PET Imaging in Alzheimer and Vascular Cognitive Impairment Patients With Significant White Matter Disease

  NCT02330510· Source

• Completed

  A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer

  NCT02163694· Phase 3· Source

• Terminated

  Telmisartan vs. Perindopril in Mild-Moderate Alzheimer's Disease Patients

  NCT02085265· Phase 2· Source

• Completed

  Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer

  NCT02003924· Phase 3· Source

• Completed

  Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma

  NCT01909453· Phase 3· Source

• Completed

  Vascular Events In Surgery patIents cOhort evaluatioN - Cardiac Surgery

  NCT01842568· Source

Trial sites

• Division of Neurosurgery, Sunnybrook Health Sciences Centre1 trial
• Duplicate_Sunnybrook Health Sciences Ctr /ID# 1248821 trial
• Neuropsychopharmacology Research Group, Sunnybrook1 trial
• Sunnybrook2 trials
• Sunnybrook Health Science Centre11 trials
• Sunnybrook Health Science Centre (Site 0304)1 trial
• Sunnybrook Health Sciences Center21 trials
• Sunnybrook Health Sciences Centre188 trials
• Sunnybrook Health Sciences Centre - Bayview Campus4 trials
• Sunnybrook Health Sciences Centre /ID# 2191031 trial
• Sunnybrook Health Sciences Centre /ID# 2519661 trial
• Sunnybrook Health Sciences Centre /ID# 2732071 trial
• Sunnybrook Health Sciences Centre /ID# 2768441 trial
• Sunnybrook Health Sciences Centre (Site # 0204)1 trial
• Sunnybrook Health Sciences Centre (Site 1501)1 trial
• Sunnybrook Health Sciences Centre - Sunnybrook Research Institute1 trial
• Sunnybrook Health Sciences Centre Toronto1 trial
• Sunnybrook - St. John's Rehab1 trial
• University of Toronto/Sunnybrook Health Sciences Center1 trial
• University of Toronto / Sunnybrook Health Sciences Centre2 trials

Conditions

Diseases this institution publishes on or runs trials for.

• Prostate cancer82 works · 27 trials
• Depression25 works · 12 trials
• Metastatic breast cancer21 works · 15 trials
• Kidney cancer21 works · 1 trials
• Neuroendocrine tumours19 works · 6 trials
• Frontotemporal dementia19 works · 9 trials
• ALS (motor neurone disease)17 works · 9 trials
• Head and neck cancer15 works · 8 trials
• Myelodysplastic syndromes10 works · 4 trials
• IgA nephropathy4 works · 3 trials